Published: May 30, 2014
DALLAS — Large proportions of patients starting on dimethyl fumarate (Tecfidera) for multiple sclerosis appear to need additional medications to manage the drug’s gastrointestinal and other adverse effects, and a substantial minority are ultimately unable to tolerate the drug, multiple studies reported here found.
These findings were confirmed in the manufacturer’s own studies — for example, more than half of patients in an open-label study took over-the-counter medications to control stomach upset and diarrhea — although symptoms eventually abated in those who stayed on the drug beyond 2 months.
On the other hand, one-quarter of patients switching to dimethyl fumarate from another MS medication in an independent study had stopped the drug within 3 months.
These and other reports on dimethyl fumarate’s safety were presented during a poster session at the joint meeting of the Consortium of Multiple Sclerosis Centers and the Americas Committee for Treatment and Research in Multiple Sclerosis (CMSC-ACTRIMS).
……..
To comment – click the comment link shown below
Share our Articles with others
……
MS Views and News / Stu’s Views & MS News
provides education, information and resources
for those affected by Multiple Sclerosis
To Keep CURRENT and up to date with MS News and Information
Sign-up at: www.msviewsandnews.org
WATCH OUR MS EDUCATIONAL VIDEOS by Topic, found here: www.youtube.com/msviewsandnews
JOIN our Facebook Page: www.facebook.com/msviewsandnews
WATCH OUR MS EDUCATIONAL VIDEOS by Topic, found here: www.youtube.com/msviewsandnews
JOIN our Facebook Page: www.facebook.com/msviewsandnews
————-
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews